AMBUJACEM’s topline: 8–10% volume CAGR (premium/trade mix shift) with 1–2% annual realization uplift; Bottomline: 15–20% PAT CAGR (cost/ton decline, EBITDA leverage); Margins: 15–18% EBITDA (base case) with structural upside from green power/logistics efficiency.
📊 Base Case (50% Probability)
Key Variables: (1) Sanghi/Penna utilization hits 80% by Jun ’26; (2) Green power approvals by Q1 FY27.
Outcome: Cost/ton declines to INR3,800 by Mar ’27 (INR3,650 by Mar ’28), driving EBITDA/ton to INR900–1,000. Volume growth at 8–10% (double industry rate) via trade premiumization. Margin expansion: EBITDA margins improve to 15–16%. FCF neutral: INR10,000cr capex funded via internal accruals (0 debt).
LODHA’s topline resilience (20–25% YoY growth) hinges on execution catch-up and land monetization; bottomline leverage (EPS +15–20%) tied to margin discipline and data center scalability; structural premiumization limits volume upside but protects margins.
📊 Base Case (50% Probability)
ITC’s topline resilience (7-9% revenue growth) hinges on premium FMCG execution and agri/packaging import safeguards, while bottomline risks (EBITDA margins, PAT volatility) stem from structural tax/import pressures and exceptional item distortions; FoodTech and sustainability initiatives offer optionality but lack near-term monetization clarity.
📊 Base Case (50% Probability)
Key Variables: Tax hikes absorbed via premiumization, MIP extended, FoodTech GMV doubles.
SBI outlook spans three scenarios: Base Case with stable NIM at 3.0% and ROE near 21%; Bear Case with margin compression to 2.8% amid NPL stress; Bull Case with NIM expansion above 3.1% and ROE exceeding 22%.
📊 Base Case (50% Probability)
Key Variables: (1) Corporate credit growth sustains at 13–15% with term loan mix improvement, (2) CASA ratio holds at 39–40%.
Outcome: NIM stabilizes at 3.0%, credit costs at 0.30–0.35%, and fee income grows 15–20% YoY (CVE + mutual fund dividends). ROA 1.0–1.1%, ROE 20–21%. Trigger: Budgetary infrastructure spend and MSME “champion” initiatives drive RAM growth; YONO scales to 15 crore users.
APARINDS’ topline likely tracks 20%+ CAGR on domestic resilience (renewables, railways, data centers) and U.S. order rebound, but margins face 100–150 bps compression from tariffs/commodities; bottomline hinges on capex utilization timing and transmission catch-up in H2 FY26.
📊 Base Case (50% Probability)
PRESTIGE’s topline hinges on NCR/Gurgaon execution and Hyderabad’s Golden Grove demand; bottomline sensitive to margin mix and land cost discipline; annuity scaling (office/retail) critical for FY30+ margin expansion but faces leasing timeline risks.
📊 Base Case (50% Probability)
Key Variables: Gurgaon parcels launch H1FY27 + Golden Grove 50% sell-through.
DIXON’s growth depends on smartphone recovery (60–65M units) and JV revenue (₹1,000+ cr by FY27). Margins hinge on PLI 2.0 and integration. Base case: 10–12% revenue growth, 20–30 bps EBITDA gain; bear case: 10–15% EPS hit if memory/Vivo delays persist.
📊 Base Case (50% Probability)
TVSMOTOR’s topline resilience (domestic premiumization + export recovery) and EBITDA expansion (scale/cost levers) are probable, but margin volatility hinges on EV execution and commodity pass-through; Norton’s cash burn remains the wild card for FCF and ROIC.
📊 Base Case (50% Probability)
Sun Pharma’s topline growth is milestone-dependent and exposed to US generics structural decline, while bottom-line resilience hinges on tax rate stabilization and R&D productivity; margins face near-term pressure from launch costs but could inflect in FY28 if innovative scales and OAI risks abate—model 31–33% EBITDA as the new range.
📊 Base Case (50% Probability)
L&T’s FY27 outcomes diverge across scenarios. Revenue growth spans 10–17%, with P&M margins between 7.5–9.0% and NWC/Revenue ranging 7–13%. EPS shifts from –8% to +20% YoY, shaped by Middle East orders, domestic capex trends, and new ventures in semiconductors and electrolyzers.
📊 Base Case (50% Probability)